View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
April 9, 2017

AbbVie reports positive results from Phase IIb trial of elagolix for uterine fibroids

AbbVie and Neurocrine Biosciences have reported positive results from a Phase IIb clinical trial of elagolix to minimise menstrual bleeding in women with uterine fibroids.

AbbVie and Neurocrine Biosciences have reported positive results from a Phase IIb clinical trial of elagolix to minimise menstrual bleeding in women with uterine fibroids.

Elagolix is an orally administered, short-acting molecule being developed to block endogenous gonadotropin-releasing hormone (GnRH) signalling.

The trial results showed that 300mg elagolix met the primary efficacy endpoint by decreasing heavy menstrual bleeding.

The 24-week, multi-centre, double-blind, randomised, placebo-controlled, parallel group Phase II M12-813 trial assessed the efficacy and safety of elagolix alone or in combination with estradiol / norethindrone acetate add-back therapy compared to placebo.

The trial was performed in 567 pre-menopausal women aged 18-51 at 100 sites in the US, Canada, Puerto Rico, Chile and the UK.

AbbVie chief medical officer and development vice-president Rob Scott said: "Current non-surgical treatments indicated for uterine fibroids are limited, and women suffering from heavy menstrual bleeding associated with uterine fibroids need more options.

"Current non-surgical treatments indicated for uterine fibroids are limited, and women suffering from heavy menstrual bleeding associated with uterine fibroids need more options."

"The positive results from this clinical trial represent a significant milestone in the development of elagolix, support AbbVie's ongoing Phase III uterine fibroids research and demonstrate our continued commitment to address complex and serious diseases."

The primary endpoint of the trial is to measure the change in menstrual blood loss at month six using the alkaline hematin method.

A significant decrease in the number of heavy bleeding days and increase in the haemoglobin concentration were observed at month six.

It was found that elagolix was well-tolerated, minimised symptom severity and improved quality of life.

The firm's Phase III uterine fibroids programme includes study of elagolix under two replicate, six-month efficacy and safety trials and a six-month safety and efficacy extension study.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena